Mechanism of cisplatin resistance in gastric cancer and associated microRNAs Changqing LiuShan LiYunlian Tang Review Article 03 August 2023 Pages: 329 - 340
Quantitative proteomics profiling reveals the inhibition of trastuzumab antitumor efficacy by phosphorylated RPS6 in gastric carcinoma Chun-Ting HuShao-Jun PeiGuo-Hui Fu Original Article 28 July 2023 Pages: 341 - 355
Chemotherapy periodization to maximize resistance training adaptations in oncology Jonathan H. C. NunesPaola S. CellaRafael Deminice Original Article 15 August 2023 Pages: 357 - 367
A clinical trial of zosuquidar plus gemtuzumab ozogamicin (GO) in relapsed or refractory acute myeloid leukemia (RR AML): evidence of efficacy based on leukemic blast P-glycoprotein functional phenotype John F. MarcellettiBranimir I. Sikic Original Article 21 August 2023 Pages: 369 - 380
Clinical significance of KL-6 in immune-checkpoint inhibitor treatment for non-small cell lung cancer Kenji NakahamaMotohiro IzumiTomoya Kawaguchi Original Article 22 August 2023 Pages: 381 - 390
Influence of CYP3A5 and ABCB1 polymorphisms on the pharmacokinetics of vincristine in adult patients receiving CHOP therapy Junichi NakagawaTakenori TakahataTakenori Niioka Original Article 23 August 2023 Pages: 391 - 398
Population pharmacokinetics and pharmacogenetics analyses of imatinib in Chinese patients with chronic myeloid leukemia in a real-world situation Shiyu HeQianhang ShaoQian Jiang Original Article 25 August 2023 Pages: 399 - 410
Pharmacokinetics, safety, tolerability, and feasibility of apatinib in combination with gefitinib in stage IIIB-IV EGFR-mutated non-squamous NSCLC: a drug-drug interaction study Yuxiang MaQun ChenHongyun Zhao Clinical Trial Report 31 July 2023 Pages: 411 - 418